Subject index of volume 107

Abuse liability assessment 315
Acetylcholine 415, 437, 541
ACTH 50
Activation 50
Activity 385
Acute 405
Acute tolerance 511
α_2-adrenoceptors 132, 497
Aetiology 97
Age 485
Aggression 297, 551
Aging 78, 144, 437
Agonistic behavior 551
AJ 76 73
Akathisia 23
Alcohol 125, 180, 551
Alcohol withdrawal 97
Alpha-methyl-*p*-tyrosine 39
Alpha-2 receptor 575
Alprazolam 535
Alzheimer's disease 437
1-Aminocyclopropanecarboxylic acid 489
Amnesia 347
Amphetamine 140, 271, 290, 297, 331, 337
d-Amphetamine 55, 425
Analgesia 595
Animal behavior 551
Anorexia 140, 359
Antidepressant 1
Antidepressants 474, 497, 569
Antipsychotic drugs 503
Anxiety 135, 347, 379
Apomorphine 341, 431
Arousal 442
Arousal modulation theory 442
Attention 394, 425, 541

Barbiturates 125
Basal forebrain 541
Behavior 1, 55, 78, 103, 217
Behavioral economics 211
Behavioral experience 290
Behavioural development 221
Benzodiazepine 347
Benzodiazepine antagonists 103
Benzodiazepine receptors 180, 310
Benzodiazepines 69, 103, 125, 379
Betablockers 61
Bicuculline 541
Bipolar disorder 503
Blood pressure 535
BMY 21502 485
Bromocriptine 277
[^{3}H]Bromoxidine (UK 14304) 132
Bupropion 303
Burying behaviour 61

Caffeine 55
Calcitonin 50
cAMP 1
Cardiac vagal control 535
Catalepsy 117
Ca^{2+} channel inhibitors 447
CGRP 50
Chlordiazepoxide 310
m-Chlorophenylpiperazine 229
Chronic 405
Chronic schizophrenia 175
Cigarette 442
Cigarette smoking 211
Circling 303
CL 218,872 347
Classical conditioning 365
Clonidine-induced behaviours 497
[^{3}H]Clonidine 132
Cocaine 55, 73, 186, 217, 221, 271, 523
Cocaine recognition site 186
Coffee drinking 211
Cognition 394, 437
Cognition enhancers 144
Cognitive dysfunction 485
Cognitive performance 83
Concurrent reinforcers 211
Conditioned place aversion 453
Conditioned place preference 221, 385, 453, 564
Conditioned withdrawal 517
Conditioning 277, 523
Contingent sensitization 290
Core body temperature 341
Corticosterone 229, 331
Cortisol 50
Craving 523
Cue learning 347

Defense 457
Dementia 144
Deoxyglucose 30
Dependence 480
Depression 503, 569
Diazepam 11, 61, 347, 405
Differential-reinforcement-of-low-rate (DRL) 72-s 474
Discrimination 541
Discriminative stimulus 117
Discriminative-stimulus effects 217
L-dopa 203
Dopamine 160, 203, 277, 285, 303, 394, 415, 431
Dopamine autoreceptor 73
Dopamine receptor subtypes 18
Dopamine receptors 23
Dopamine release 303
Dopamine system 453
DR mice 125
Drinking behavior 447
Drug discrimination 73, 103, 303
Drug interactions 217
Drug plasma concentration 11
Drug self-administration 211, 315
Drug sensitivity 11
DS mice 125
D1 agonist 217
D2 agonist 217
D-2 antagonists 236
D_1, D_2 DA receptors 39
D_2 agonist 415
D_2 receptors 277

EEG 569
EEG activity 236
Electroconvulsive shock 497
Electroencephalogram 195
Electrophysiology 1
Elevated X-maze 405
Endogenous 69
Ethanol 11, 78, 125, 132, 337, 385, 447, 453, 511, 564
Ethology 551
Ethopharmacology 457
Evoked brain potentials 50
Exploratory behaviour 415
Extrapyramidal syndromes 18

Feeding rate 359
Fenfluramine 327
Fentanyl 319
Field potentials 195
Fixed-ratio schedule 315
Flesinoxan 474
Flight 457
Flumazenil 103, 180, 310, 347
Flunitrazepam 11
Fluoxetine 1, 359
Fluprazine 113
Food intake 113, 447
Forced swim test 489
Frequency analysis 195
Frontal cortex 415
FR-10 511

GABA 541
GBR 12909 186
Generalized anxiety disorder 535
Gepirone 135
Glycine 489
Goe 5438 447
Guinea-pig 581

Haloperidol 18, 290, 331, 453
Hamster 517
HAS/LAS 564
Heart rate 523, 535
High 352
Hippocampus 415
5-HT 379
5-HT_1 antagonists 61
5-HT_2 receptors 135
5-HT_3 receptors 140
5-HT_{1A} agonist 474
5-HT_{1A} receptors 135
5-HT_{1c} receptor and 5-HT_2 receptor 327
5-HT_{1C} receptors 379
Human 255
Human brain 132, 180
Human breast milk 69
Human subjects 535
Humans 211, 319, 352
6-Hydroxydopamine 203, 285
5-Hydroxytryptamine 373
8-Hydroxy-2(di-N-propylamino)tetralin 30
Hypoactivity 497

Idazoxan 405
Imipramine 535
Inbred mice 385
Inbred mice (DBA/2J) 453
Indatraline 186

Subject index of volume 107

Abuse liability assessment 315
Acetylcholine 415, 437, 541
ACTH 50
Activation 50
Activity 385
Acute 405
Acute tolerance 511
α_2-adrenoceptors 132, 497
Aetiology 97
Age 485
Aggression 297, 551
Aging 78, 144, 437
Agonistic behavior 551
AJ 76 73
Akathisia 23
Alcohol 125, 180, 551
Alcohol withdrawal 97
Alpha-methyl-*p*-tyrosine 39
Alpha-2 receptor 575
Alprazolam 535
Alzheimer's disease 437
1-Aminocyclopropanecarboxylic acid 489
Amnesia 347
Amphetamine 140, 271, 290, 297, 331, 337
d-Amphetamine 55, 425
Analgesia 595
Animal behavior 551
Anorexia 140, 359
Antidepressant 1
Antidepressants 474, 497, 569
Antipsychotic drugs 503
Anxiety 135, 347, 379
Apomorphine 341, 431
Arousal 442
Arousal modulation theory 442
Attention 394, 425, 541

Barbiturates 125
Basal forebrain 541
Behavior 1, 55, 78, 103, 217
Behavioral economics 211
Behavioral experience 290
Behavioural development 221
Benzodiazepine 347
Benzodiazepine antagonists 103
Benzodiazepine receptors 180, 310
Benzodiazepines 69, 103, 125, 379
Betablockers 61
Bicuculline 541
Bipolar disorder 503
Blood pressure 535
BMY 21502 485
Bromocriptine 277
[^{3}H]Bromoxidine (UK 14304) 132
Bupropion 303
Burying behaviour 61

Caffeine 55
Calcitonin 50
cAMP 1
Cardiac vagal control 535
Catalepsy 117
Ca^{2+} channel inhibitors 447
CGRP 50
Chlordiazepoxide 310
m-Chlorophenylpiperazine 229
Chronic 405
Chronic schizophrenia 175
Cigarette 442
Cigarette smoking 211
Circling 303
CL 218,872 347
Classical conditioning 365
Clonidine-induced behaviours 497
[^{3}H]Clonidine 132
Cocaine 55, 73, 186, 217, 221, 271, 523
Cocaine recognition site 186
Coffee drinking 211
Cognition 394, 437
Cognition enhancers 144
Cognitive dysfunction 485
Cognitive performance 83
Concurrent reinforcers 211
Conditioned place aversion 453
Conditioned place preference 221, 385, 453, 564
Conditioned withdrawal 517
Conditioning 277, 523
Contingent sensitization 290
Core body temperature 341
Corticosterone 229, 331
Cortisol 50
Craving 523
Cue learning 347

Defense 457
Dementia 144
Deoxyglucose 30
Dependence 480
Depression 503, 569
Diazepam 11, 61, 347, 405
Differential-reinforcement-of-low-rate (DRL) 72-s 474
Discrimination 541
Discriminative stimulus 117
Discriminative-stimulus effects 217
L-dopa 203
Dopamine 160, 203, 277, 285, 303, 394, 415, 431
Dopamine autoreceptor 73
Dopamine receptor subtypes 18
Dopamine receptors 23
Dopamine release 303
Dopamine system 453
DR mice 125
Drinking behavior 447
Drug discrimination 73, 103, 303
Drug interactions 217
Drug plasma concentration 11
Drug self-administration 211, 315
Drug sensitivity 11
DS mice 125
D1 agonist 217
D2 agonist 217
D-2 antagonists 236
D_1, D_2 DA receptors 39
D_2 agonist 415
D_2 receptors 277

EEG 569
EEG activity 236
Electroconvulsive shock 497
Electroencephalogram 195
Electrophysiology 1
Elevated X-maze 405
Endogenous 69
Ethanol 11, 78, 125, 132, 337, 385, 447, 453, 511, 564
Ethology 551
Ethopharmacology 457
Evoked brain potentials 50
Exploratory behaviour 415
Extrapyramidal syndromes 18

Feeding rate 359
Fenfluramine 327
Fentanyl 319
Field potentials 195
Fixed-ratio schedule 315
Flesinoxan 474
Flight 457
Flumazenil 103, 180, 310, 347
Flunitrazepam 11
Fluoxetine 1, 359
Fluprazine 113
Food intake 113, 447
Forced swim test 489
Frequency analysis 195
Frontal cortex 415
FR-10 511

GABA 541
GBR 12909 186
Generalized anxiety disorder 535
Gepirone 135
Glycine 489
Goe 5438 447
Guinea-pig 581

Haloperidol 18, 290, 331, 453
Hamster 517
HAS/LAS 564
Heart rate 523, 535
High 352
Hippocampus 415
5-HT 379
5-HT_1 antagonists 61
5-HT_2 receptors 135
5-HT_3 receptors 140
5-HT_{1A} agonist 474
5-HT_{1A} receptors 135
5-HT_{1c} receptor and 5-HT_2 receptor 327
5-HT_{1C} receptors 379
Human 255
Human brain 132, 180
Human breast milk 69
Human subjects 535
Humans 211, 319, 352
6-Hydroxydopamine 203, 285
5-Hydroxytryptamine 373
8-Hydroxy-2(di-N-propylamino)tetralin 30
Hypoactivity 497

Idazoxan 405
Imipramine 535
Inbred mice 385
Inbred mice (DBA/2J) 453
Indatraline 186

Indorenate 61
Insomnia patients 480
Interaction 511
Interdose interval 290
Interindividual differences 11
Interval analysis 551
Intoxication 97
Ipsapirone 61, 405
IRT>t schedule 373

Ketamine 431
Ketanserin 135, 359, 379

Latent inhibition 425
Lateralisation of function 425
Learning 55, 243, 365, 394, 485, 530
Lesch-Nyhan syndrome 39
Lesion 373
Liking 352
Locomotion 277, 297, 551
Locomotor 337
Locomotor activity 229, 453, 564, 581
Locomotor behavior 595
Locomotor stimulation 125
Loperamide 89
Lu 19-005 186
LY 171555-induced hyperactivity 591
LY53857 327

Mammillary gland 69
Man 425
Marijuana 117, 255
Mecamylamine 530
Memory 83, 394, 437, 530
Mesolimbic dopamine 285
Metachlorophenylpiperazine 30
Metergoline 359
Methamphetamine 303
3-Methoxytyramine 303
Methylnaloxone 89
Mianserin 379
Milk intake 290
MK-801 243, 431, 489
MK-801 induced hypermotility 591
Monoamine uptake inhibitor 186
Mood 319
Morphine 55, 89, 385, 517, 581
Morphine pellets 517
Morris water maze 347, 485
Motivation 160
Motor activity 297, 551
Motor control 160
Mouse 221, 310
Muscimol 541
Mydriasis 497

Naloxone 310, 517, 575
Neuroendocrine 1
Neuroleptic 117
Neuroleptics 18, 175, 195, 236
Neurotransmitters 229
Nicotine 271, 285, 442
Nicotinic cholinergic receptors 530
Nictitating membrane response 365
Nitrous oxide 310
N-methyl-D-aspartate 489
N,N-dimethylamphetamine 315
Nonhuman primates 18
Nootropics 144
Noradrenaline 415, 575
Normals 480
Novelty hypoalgesia 575
Nucleus accumbens 285

Object recognition 415
Ondansetron 140, 405
Ontogeny 39
Ontogeny of locomotor activity 221
Operant 511
Operant behavior 186
Operant behaviour 373
Opiate 117
Opiate withdrawal 595
Opiates 297, 319

Para-chloroamphetamine 327
Parkinson's disease 203, 394
Pavlovian conditioning 203
Pentobarbital 352
Pentylenetetrazol 457
D-Pen^2, D-Pen^5 enkephalin 581
Pharmacogenetics 385
Pharmacokinetics 352
Phenylpiperazine 113
Physostigmine 541
Place conditioning 385
Place learning 3473
Placebo controlled trial 175
Plus-maze test 135
Positron emission tomography 23, 180
Postsynaptic α_2-adrenoceptors 497
Precipitated withdrawal 517
Preference 447
Presynaptic α_2-adrenoceptors 497
Prolactin 229
Psychogenetic selection 415
Psychomotor performance 11, 319
Psychomotor stimulant theory 385

Quinpirole 39, 217, 341, 581
Quipazine 30

Rabbit 236, 365
Raclopride 23
Radial maze 415
Radioreceptor assay 69, 186
Rat 97, 195, 236, 347, 373, 405, 457, 474, 575, 591
Rate of increase 352
Rats 113, 117, 243, 511, 564
Reaction time 78
Rearing 337
Rebound insomnia 480
Receptors 1
Receptors, 5-HT_{1a}, 5-HT_{1b}, 5-HT_2 229
Rehearsal 263
Reinforcement 285
Reinforcer interactions 211
Reinforcing effects 255
Reinforcing effects of drugs 315
Relapse prevention 175
Relapse rates 175
Remoxipride 175, 236
Repeated acquisition 55, 243
Repeated transitions 243
Repeated treatment 591
Reserpine 39
Reserpine and mice 341
Respiratory sinus arrhythmia 535
Response chains 55
Reward 385, 453
Ritanserin 405
Roman strains 415
Route of administration 217, 255
RU 41656 415

Saccharin consumption 447
SCH 23390 341, 591
Schizophrenia 425, 503
SCH 23390 18, 23
Scopolamine 243, 263, 437
Sedation 236, 347, 497
Seizures 97
Selective breeding 125
Self-administration 255, 271
Self-mutilation 39
Sensitization 271, 277, 290, 331
Sensorimotor function 160
Sensory processing 50
Sequential analysis 551
Serotonin 1, 30, 229, 327, 415, 474
Sexual behavior 89, 327
Sibutramine hydrochloride 303, 497
SKF 38393 39, 217, 341, 431
Skin resistance 523
Skin temperature 523
Sleep 83, 569
Smoking 442
Smoking motive 442
Social interaction 379
Sodium cromoglycate 595
Sodium pentobarbital 365
Spatial alternation behavior 263
Spontaneous alternation 415
Spontaneous locomotion 347
Squirrel monkeys 55, 217, 315
Staircase test 310
Stereoisomers 315
Stereoselectivity 186
Stereotypy 431
Stress 331, 442
Striatum 415
Subjective effects 255, 319
Submission 457
Sulpiride 341

Tardive dyskinesia 503
Taurine 337
Telemetry 195
Temperature dependence 186
Temporal differentiation 373
Δ^9-Tetrahydrocannabinol 55, 117
THC 255
Thigmotaxis 347
Tolerance 78, 511
Trazodone 569
Triazolam 83, 480
Triazolopyridazine 347

(+)-UH 232 73
U50,488H 581

Water intake 113
Withdrawal 297, 405, 523
Working memory 263, 415

YM 09151-2 591

Zolpidem 83